PMID: 9537209Apr 16, 1998Paper

A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study

American Journal of Clinical Oncology
S YalçinD Firat

Abstract

The efficacy of diflunisal in cancer pain was evaluated and compared with dipyrone. Diflunisal was given at the dosage of 500 mg perorally twice a day, and dipyrone was given at the dosage of 500 mg perorally three times a day. Duration of each treatment was 7 days; after a 12-hour wash-out period, patients were given the other drug for another 7 days. A total of 50 patients were enrolled in the study. Pain intensity was assessed by 10-point visual analog scale (VAS). Patients who had a VAS score higher than 5 were included. A total of 47 patients were evaluable. Initial VAS score was a mean of 8.57+/-1.33. Diflunisal reduced the pain score by a mean of 4.65+/-3.10, whereas dipyrone reduced the pain score by a mean of 3.25 < or = 2.85 (p < 0.001). Patients were also analyzed in three subgroups according to the presence of nonmetastatic, metastatic, and bone metastatic diseases. In each of these subgroups, diflunisal reduced the pain score more than dipyrone; however, the difference was statistically significant only in patients who had bone metastasis. Adverse reactions were rare and acceptable with both drugs. Diflusinal is superior to dipyrone at this dosage and schedule in the treatment of moderate to severe cancer pain.

References

Aug 1, 1983·Clinical Pharmacology and Therapeutics·K SriwatanakulG Mehta
Nov 1, 1982·Cancer·R L Daut, C S Cleeland
Jul 21, 1993·Journal of the National Cancer Institute·D J Wilkie
Jan 1, 1997·Acta Oncologica·S YalçinC Savaş

❮ Previous
Next ❯

Citations

Oct 28, 1998·Medical Oncology·S YalçinG Tekuzman
Apr 23, 2004·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·D J Casarett, J Karlawish
Apr 23, 2004·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·D CasarettD A Asch
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ewan McNicolDaniel Carr
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine MiaskowskiPeter Koo
Jul 13, 2017·The Cochrane Database of Systematic Reviews·Sheena DerryBee Wee
Oct 31, 2018·Journal of Cachexia, Sarcopenia and Muscle·Robert H SchüchenRupert Conrad
Aug 23, 2019·Journal of Clinical Pharmacology·Mathias Lutz
Aug 1, 2015·The Cochrane Database of Systematic Reviews·Ewan D McNicolDaniel B Carr
Mar 10, 2001·Cancer Treatment Reviews·S Mercadante

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.